GL261 Orthotopic Mouse Model Service for Brain Cancer

The GL261 orthotopic mouse model for brain cancer represents the most extensively characterized syngeneic glioblastoma platform available, enabling preclinical evaluation of novel therapeutics within a fully immunocompetent C57BL/6 host that preserves the blood-brain barrier, tumor-associated immunosuppression, and invasive growth dynamics intrinsic to high-grade glioma. Alfa Cytology provides this specialized orthotopic model service with comprehensive technical capabilities spanning stereotactic cell implantation, longitudinal bioluminescence and MRI monitoring, immune profiling, and multi-modal endpoint analysis—delivering the rigorous, reproducible data required to advance your brain cancer therapeutic pipeline from discovery through late-stage preclinical development.

Overview of GL261 Orthotopic Mouse Model for Brain Cancer

The GL261 glioma line was originally induced in 1970 via intracranial implantation of 3-methylcholanthrene into C57BL/6 mice and subsequently maintained through serial intracranial and subcutaneous passages on its syngeneic host. Histologically, GL261 tumors display anaplastic pleomorphic cells with atypical nuclei, elevated mitotic activity, and focal pseudopalisading necrosis—features that partially recapitulate human glioblastoma multiforme (GBM) architecture. The cells stain positive for glial fibrillary acidic protein (GFAP) and S100 protein, and they harbor a constellation of genetic alterations including an upregulating p53 mutation, an activating K-ras mutation at codon 12, elevated c-myc expression, and secondary PTEN downregulation with PI3K pathway activation. When cultured under serum-free conditions, GL261 cells express CD133 and exhibit enhanced tumorigenicity and immunogenicity, offering a tractable system for investigating glioma stem cell biology.

Fig 1. GL261 in situ model MRI/PET fusion imaging (Tspo -/- mice, coronal/transverse sections) and IHC (H&E/Iba-1/GFAP). (Banati, Richard B., et al., 2020)

As a syngeneic model, GL261 can be orthotopically implanted into immunocompetent C57BL/6 mice without rejection, a feature that distinguishes it from human xenograft systems and makes it the preeminent platform for immuno-oncology studies in brain cancer. The model exhibits a high neoantigen load and expresses unique tumor antigens including HMP/AN2, EphA-2, and GARC-1, rendering it particularly responsive to dendritic cell vaccines, checkpoint inhibitors, and cytokine-directed therapies. Tumor cells exhibit diffuse infiltration into surrounding parenchyma, robust angiogenesis, and central necrotic regions surrounded by hypercellular rims—physiological hallmarks that influence drug distribution, hypoxia-driven resistance, and immune cell trafficking in ways that flank or subcutaneous models cannot replicate.

Cell Line Information: GL261

The table below provides a detailed characterization of the GL261 murine glioma cell line to support experimental planning and model selection for brain cancer preclinical studies.

Our Services

Alfa Cytology delivers a comprehensive GL261 orthotopic mouse model service engineered to meet the demands of modern brain cancer preclinical research, encompassing stereotactic surgical implantation, non-invasive longitudinal imaging, immune microenvironment profiling, and detailed histopathological and molecular endpoint characterization. Our experienced neuro-oncology team ensures reproducible tumor kinetics, stringent quality control, and flexible study configurations that integrate seamlessly with your therapeutic development objectives.

Workflow of GL261 Orthotopic Mouse Model Construction

Construction of the GL261 orthotopic glioma model employs a refined stereotactic surgical protocol optimized for high engraftment rates, minimal surgical morbidity, and consistent tumor growth kinetics. The workflow integrates cell quality verification, precision neurosurgical technique, and longitudinal multimodal monitoring to generate robust, publication-quality preclinical datasets.

1. Cell Line Authentication and Expansion: GL261 cells are authenticated by STR profiling and expanded under optimized culture conditions to ensure genetic stability, viability >95%, and consistent tumorigenic potential prior to surgical preparation.
2. Host Selection and Acclimatization: Syngeneic C57BL/6 mice—typically 6–8 weeks old and 18–22 g—are acclimatized for at least one week, with health screening and baseline body weight recording to minimize inter-animal variability.
3. Anesthesia and Surgical Preparation: Mice are anesthetized with isoflurane (induction 2.5%, maintenance 1–2%) delivered via nose cone on a stereotactic frame equipped with a warming pad; the scalp is shaved and sterilized with alternating chlorhexidine and saline swabs.
4. Stereotactic Coordinate Calibration: Bregma is identified after periosteum removal with 3% hydrogen peroxide; a 0.9 mm burr hole is drilled at coordinates 2 mm lateral and 2 mm posterior to bregma, corresponding to the right striatum/caudate putamen.
5. Intracranial Cell Injection: A Hamilton syringe loaded with 2–5 µL of GL261 cell suspension (2.5–5 × 10⁴ cells in PBS, with or without Matrigel) is inserted to a depth of 4 mm, withdrawn 1 mm to create a pocket, and cells are slowly injected over 2–6 minutes; the needle is held in place for 1 minute to prevent backflow.
6. Cranial Closure and Postoperative Care: The burr hole is sealed with bone wax, the scalp incision is closed with surgical adhesive or sutures, and mice are recovered on a heated pad with analgesic support per institutional animal care guidelines.
7. Tumor Establishment Verification: Tumor growth is confirmed 5–7 days post-implantation via bioluminescence imaging (for luciferase-expressing lines) or contrast-enhanced micro-CT; mice are randomized into treatment cohorts once baseline tumor signals are established.
8. Longitudinal Monitoring and In-Life Assessment: Tumor burden is tracked weekly via bioluminescence imaging, T2-weighted MRI, or micro-CT; body weight, neurological signs (Karnofsky-like score), and overall clinical condition are recorded concurrently.
9. Treatment Administration: Investigational agents—including checkpoint inhibitors, oncolytic viruses, targeted small molecules, or combination regimens—are administered according to protocol-defined schedules via intracranial, intravenous, intraperitoneal, or oral routes as appropriate.
10. Endpoint Analysis and Necropsy: At study termination, brains are harvested en bloc, photographed, and sectioned coronally; tumor dimensions are measured, and tissue aliquots are allocated for formalin-fixed paraffin embedding, snap-freezing, and downstream molecular analysis.
11. Histopathological and Molecular Characterization: Tumor sections undergo H&E staining, IHC for GFAP, Ki-67, CD31, PD-L1, and phospho-AKT, alongside flow cytometry of tumor-infiltrating lymphocytes and myeloid subsets to characterize immune modulation and pathway engagement.
12. Data Integration and Reporting: All imaging, survival, biometric, and molecular data are compiled into a comprehensive study report with Kaplan-Meier survival curves, tumor growth kinetics, immunophenotyping summaries, and pharmacodynamic interpretations.

Fig 2. GL261 Orthotopic Mouse Model construction workflow

Case Study-GL261 Orthotopic Mouse Model Development

In a recent preclinical engagement, the GL261 orthotopic glioma model was established with highly reproducible tumor take and aggressive intracranial growth kinetics amenable to multi-week therapeutic intervention windows. Treatment cohorts receiving a PD-1 checkpoint inhibitor demonstrated dose-dependent prolongation of median survival relative to vehicle controls, accompanied by increased CD8+ T-cell infiltration and reduced regulatory T-cell burden within the tumor microenvironment as assessed by flow cytometry. A parallel combination arm pairing the checkpoint inhibitor with a tumor-targeting oncolytic viral vector showed enhanced therapeutic synergy, with a subset of animals achieving long-term survival beyond 60 days. Detailed quantitative datasets—including bioluminescence tumor growth curves, survival metrics, neurological scoring trends, and immune profiling data—are available for review; please reach out to our scientific team to discuss how these findings can inform your specific brain cancer therapeutic strategy.

Why Choose Alfa Cytology?

Selecting Alfa Cytology as your GL261 orthotopic model partner means accessing a neuro-oncology-focused service platform built on surgical precision, immunological depth, and operational agility.

• Deep expertise in syngeneic brain tumor models with optimized stereotactic protocols that yield consistent GL261 engraftment and predictable survival kinetics in immunocompetent hosts.
• In-house multimodal imaging infrastructure—including bioluminescence, MRI, and micro-CT—for non-invasive longitudinal tumor monitoring and early pharmacodynamic readouts.
• Comprehensive immune profiling capabilities spanning flow cytometry, IHC, and cytokine multiplex assays to dissect tumor-microenvironment interactions and immunotherapy mechanism of action.
• Flexible study designs supporting monotherapy, combination, sequential, and biomarker-stratified arms tailored to your compound mechanism and regulatory requirements.
• Rigorous cell authentication, health surveillance, and GLP-aligned documentation practices that uphold data integrity for IND-enabling and peer-review standards.
• Dedicated neuro-oncology project scientists who provide proactive troubleshooting, adaptive timeline management, and transparent communication throughout your study lifecycle.

Contact Us

To explore how the GL261 orthotopic mouse model can accelerate your brain cancer preclinical program, we invite you to reach out to us for a confidential scientific consultation. Our neuro-oncology specialists will evaluate your therapeutic target, propose a customized study design, and outline a clear roadmap to generating the high-quality data your discovery team requires. Contact us today and let Alfa Cytology advance your next preclinical milestone in glioblastoma research.

For research use only. Not intended for any clinical use.